Systemic therapeutic approaches to advanced thyroid cancers.
Until only recently, few effective systemic therapies were available to treat patients with metastatic thyroid cancers. Recent advances in better understanding the pathogenesis and altered signaling pathways-especially in medullary and differentiated thyroid cancers (MTCs and DTCs)-have begun to change this situation substantially. Vandetanib, an orally bioavailable inhibitor of the RET kinase that is constitutively activated in MTC, has now been approved by the U.S. Food and Drug Administration (FDA) for use in progressive and symptomatic metastatic MTC; it has been shown to delay time to progression relative to placebo in a randomized phase III trial. Further, vascular endothelial growth factor receptor (VEGF-R) inhibitory agents including sorafenib, sunitinib, pazopanib, and axitinib that are already approved in the United States for use in advanced renal cell carcinoma have shown high response rates in treating advanced DTCs in multiple phase II trials, and have become commonly used in progressive radioiodine-refractory metastatic DTC. Yet additional agents are now in development, with several including XL184 (cabozantinib) also showing promise in DTC and MTC. In anaplastic thyroid cancer (ATC), progress has been slower, with the greatest apparent gains resulting more from the application of systemic therapies earlier in the disease course, especially when used in conjunction with initial surgical and radiation therapies. Despite recent progress, additional effective systemic therapeutic approaches remain sorely needed for treating metastatic MTC, DTC, and ATC.
From the Division of Medical Oncology; Division of Endocrinology, Mayo Clinic Florida, Jacksonville, FL; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Michael E
ME
Menefee
From the Division of Medical Oncology; Division of Endocrinology, Mayo Clinic Florida, Jacksonville, FL; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Robert C
RC
Smallridge
From the Division of Medical Oncology; Division of Endocrinology, Mayo Clinic Florida, Jacksonville, FL; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Keith C
KC
Bible